SwePub
Tyck till om SwePub Sök här!
Sök i LIBRIS databas

  Extended search

WFRF:(Albertsson P A)
 

Search: WFRF:(Albertsson P A) > University of Gothenburg > Polak M > Safety and Efficacy...

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist

Safety and Efficacy of Pediatric Growth Hormone Therapy: Results From the Full KIGS Cohort

Maghnie, M. (author)
Ranke, M. B. (author)
Geffner, M. E. (author)
show more...
Vlachopapadopoulou, E. (author)
Ibanez, L. (author)
Carlsson, M. (author)
Cutfield, W. (author)
Rooman, R. (author)
Gomez, R. (author)
Wajnrajch, M. P. (author)
Linglart, A. (author)
Stawerska, R. (author)
Clayton, P. E. (author)
Darendeliler, F. (author)
Hokken-Koelega, A. C. S. (author)
Horikawa, R. (author)
Tanaka, T. (author)
Dorr, H. G. (author)
Albertsson-Wikland, Kerstin, 1947 (author)
Gothenburg University,Göteborgs universitet,Institutionen för neurovetenskap och fysiologi,Institute of Neuroscience and Physiology
Polak, M. (author)
Grimberg, A. (author)
show less...
 (creator_code:org_t)
2022-09-14
2022
English.
In: Journal of Clinical Endocrinology & Metabolism. - : The Endocrine Society. - 0021-972X .- 1945-7197. ; 107:12, s. 3287-3301
  • Journal article (peer-reviewed)
Abstract Subject headings
Close  
  • Context The Kabi/Pfizer International Growth Database (KIGS) is a large, international database (1987-2012) of children treated with recombinant human growth hormone (rhGH) in real-world settings. Objective This work aimed to evaluate the safety and efficacy of rhGH from the full KIGS cohort. Methods Data were collected by investigators from children with growth disorders treated with rhGH (Genotropin [somatropin]; Pfizer). Safety was evaluated in all treated patients, and efficacy in those treated for 1 year or more. A subgroup included patients treated for 5 years or more (>= 2 years prepubertal) who had reached near-adult height (NAH). Main outcomes included adverse events (AEs), serious AEs (SAEs), and height growth. Results The full KIGS cohort (N = 83 803 [58% male]) was treated for idiopathic GH deficiency (IGHD; 46.9%), organic GHD (10.0%), small for gestational age (SGA; 9.5%), Turner syndrome (TS; 9.2%), idiopathic short stature (ISS; 8.2%), and others (16.2%). Median rhGH treatment duration was 2.7 years and observation 3.1 years. SAEs occurred in 3.7% of patients and death in 0.4%. The most common SAEs were recurrence of craniopharyngioma (n = 151), neoplasm (n = 99), and cancer (n = 91); and scoliosis (n = 91). Median first-year delta height-SD score (SDS) (Prader) in prepubertal patients was 0.66 (IGHD), 0.55 (ISS), 0.58 (TS), and 0.71 (SGA). Median gains in NAH-SDS were 1.79 (IGHD), 1.37 (ISS), and 1.34 (SGA) for boys, and 2.07 (IGHD), 1.62 (ISS), 1.07 (TS), and 1.57 (SGA) for girls. Conclusion Data from KIGS, the largest and longest running international database of rhGH-treated children, show that rhGH is safe and increases short-term height gain and adult height across GHD and non-GHD conditions.

Subject headings

MEDICIN OCH HÄLSOVETENSKAP  -- Klinisk medicin -- Endokrinologi och diabetes (hsv//swe)
MEDICAL AND HEALTH SCIENCES  -- Clinical Medicine -- Endocrinology and Diabetes (hsv//eng)

Keyword

children
short stature
growth hormone
KIGS
efficacy
safety
childhood short stature
long-term mortality
prepubertal children
adult height
pubertal changes
gh
risk
deficiency
experience
responses
Endocrinology & Metabolism

Publication and Content Type

ref (subject category)
art (subject category)

Find in a library

To the university's database

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view